201 related articles for article (PubMed ID: 21167520)
1. Editorial comment.
Eyre SJ
J Urol; 2011 Feb; 185(2):488. PubMed ID: 21167520
[No Abstract] [Full Text] [Related]
2. Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
[No Abstract] [Full Text] [Related]
3. Prostate-specific antigen dynamics and prostate cancer diagnosis.
Bartoletti R
Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
[No Abstract] [Full Text] [Related]
4. Prostate cancer screening.
Roetzheim RG; Herold AH
Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer - will we ever know?
Adolfsson J
Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
[No Abstract] [Full Text] [Related]
6. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
7. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Joniau S
Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
[No Abstract] [Full Text] [Related]
8. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Scattoni V
Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
[No Abstract] [Full Text] [Related]
9. Editorial comment.
Gupta A; Lilja H
Urology; 2011 Apr; 77(4):903-4; author reply 904. PubMed ID: 21477718
[No Abstract] [Full Text] [Related]
10. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml.
Stephan C; Jung K; Cammann H
Cancer; 2004 May; 100(9):1989-90; author reply 1989-90. PubMed ID: 15112283
[No Abstract] [Full Text] [Related]
11. Assessing risk: does this patient have prostate cancer?
Carter HB
J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
[No Abstract] [Full Text] [Related]
12. How to use PSA to screen for prostate cancer.
Little B; Young M
Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
[TBL] [Abstract][Full Text] [Related]
13. Efficacy vs effectiveness in prostate-specific antigen screening.
Albertsen PC
J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
[No Abstract] [Full Text] [Related]
14. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
Ciatto S
Eur Urol; 2010 Apr; 57(4):630. PubMed ID: 19375847
[No Abstract] [Full Text] [Related]
15. Editorial comment on: prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.
Semjonow A
Eur Urol; 2010 Apr; 57(4):629-30. PubMed ID: 19375846
[No Abstract] [Full Text] [Related]
16. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
17. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Ngo TC; Turnbull BB; Lavori PW; Presti JC
J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
[TBL] [Abstract][Full Text] [Related]
18. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
19. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Chun FK; Briganti A
Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
[No Abstract] [Full Text] [Related]
20. Prostate cancer: A challenge for screening.
Donnell RF
Surg Oncol Clin N Am; 1999 Oct; 8(4):693-702, vii. PubMed ID: 10452935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
